



Figure S6: Correlation analysis between immune responses measured by IVS ELISpot assay and clinical outcome. Correlation between the breadth of vaccine-specific T cell responses and tumor shrinkage (A) or PFS (B). C: Correlation analysis between origin of CD8⁺T cell responses (induced by the tumor and / or the vaccine) and clinical benefit. DCB: Patients with objective tumor response (PR) and/or stabilized disease (SD) for at least 38 weeks; Others: patients with no DCB. *De novo*: newly induced T cell responses (not detected before vaccination). Pre-existing: T cell responses detected at baseline with/without boosting by the vaccine; All: De novo and pre-existing T cell responses; R: Pearson correlation coefficient. Box plots show individual patient data and median, each dot represents one patient. PFS: progression-free survival. #: number